Developer docs
API playgroundTry for free, no card

Search company profiles

Amorphical

Full company profile

uuid00067lk

Namestring
Amorphical
Legal namestring
Amorphical Ltd.
Websiteurl
amorphical.com
Company typeenum
Private
Founded yearint
2004
Descriptiontext

Amorphical is a privately held Israeli biotechnology company founded in 2004 and headquartered in Ness Ziona, Israel. It develops therapeutics based on a proprietary nano-amorphous calcium carbonate (ACC) platform technology inspired by the blue crayfish's ability to store calcium in amorphous (non-crystalline) form for rapid exoskeleton regeneration. The disordered, nanometric mineral structure (10-100 nm particle size) provides approximately double the fractional calcium absorption of crystalline calcium carbonate (22.1% vs 13.7%) and dissolves preferentially in acidic microenvironments, enabling targeted delivery to sites of inflammation, tumor acidity, and metabolic dysfunction while sparing healthy tissue. The company has built a portfolio of nearly 200 patent applications (more than 130 granted) and a 3,200 sq.m. GMP/ISO/HACCP-certified production facility in the Arava Desert.

Amorphical operates four clinical-stage therapeutic programs: AMOR-1 (Phase 2 under FDA IND for hypoparathyroidism, 81 participants, demonstrating 50% dose reduction), AMOR-18 (Phase 1/2 for moderate-to-severe COVID-19 showing 0% ICU transfers/deaths vs 23% placebo), an enteric-coated ACC program for moderate-to-severe Crohn's disease (Phase 2 with 62.5% sustained remission at 48 weeks), and a Phase 2 trial for Stage IV pancreatic cancer launched at Shaare Zedek Medical Center in November 2025. In parallel, the company sells ACC-based calcium supplements directly to consumers as a higher-bioavailability alternative to conventional calcium products.

The business model combines long-term pharmaceutical development — targeting FDA-regulated approvals and potential licensing/royalty economics in bone/metabolic disease, inflammatory disease, and oncology — with a smaller near-term commercial supplements revenue stream. Clinical work is conducted exclusively through partnerships with leading Israeli medical centers, and the company has assembled a leadership team with pharmaceutical veterans from Teva (Copaxone development) and SRI International. No revenue, funding total, or commercial scale figures are publicly disclosed.

Short descriptiontext

Amorphical is an Israeli clinical-stage biotechnology company developing nano-amorphous calcium carbonate (ACC) therapeutics for hypoparathyroidism, Crohn's disease, pancreatic cancer, and COVID-19, and selling ACC-based calcium supplements directly to consumers, supported by nearly 200 patents and a GMP-certified production facility.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersNess Ziona, Israel
HQ citystring
Ness Ziona
HQ countrystring
Israel
HQ regionstring
Middle East
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
amorphous calcium carbonate, biopharmaceutical therapeutics, mineral-based medicine, calcium supplements, clinical stage drugs
Industry2 codes
PRIMARYAFAJAKAB
Minerals & Trace Elements (Calcium, Magnesium, Zinc, Iron; Chelated Minerals)
Agriculture & Food Production/Food Ingredients & Additives/Nutraceutical & Functional Ingredients (Vitamins, Minerals, Omega-3s, Botanicals)
SECONDARYHLAHAEAG
Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Ground or Treated Mineral and Earth Manufacturing327992
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Industrial Inorganic Chemicals2810
Product category
Biopharmaceuticals / Mineral Therapeutics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1ACC-based calcium supplements
TypeOne Time License
Description

Commercial sale of amorphous calcium carbonate supplements for bone health, positioning as superior alternative to conventional calcium supplements for consumers seeking enhanced bioavailability

amorphical.com
2Pharmaceutical development
TypeLicensing Royalties
Description

Development and potential future commercialization of nano-amorphous mineral therapeutics for inflammatory diseases, metabolic disorders, and oncology through FDA-regulated clinical pathways

amorphical.com
3Oncology adjunct therapy
TypeLicensing Royalties
Description

Stage IV pancreatic cancer Phase 2 clinical trial evaluating nano-amorphous mineral therapy as adjunct to standard chemotherapy, with data expected Q3 2026

amorphical.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Supply Chain, Operations, Personnel, Infrastructure, Marketing or Sales
GTM typeB2B and B2C
B2B and B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Amorphical develops and manufactures proprietary nano-amorphous calcium carbonate (ACC)-based therapeutics and supplements derived from biomimicry of the blue crayfish gastrolith. The company sells commercial ACC calcium supplements for bone health (B2C) and advances a clinical-stage pipeline of therapeutic candidates targeting hypoparathyroidism (AMOR-1, Phase 2), Crohn's disease, Stage IV pancreatic cancer, and previously COVID-19 (AMOR-18), with multiple delivery formulations including oral, inhaled, enteric-coated, and topical.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 62.5% sustained clinical remission at 48 weeks in Crohn's disease Phase 2 trial
+3 more records
Product overview1 text field

Amorphical operates as a biotechnology company offering a proprietary nano-amorphous mineral platform technology centered on Amorphous Calcium Carbonate (ACC). The company's portfolio includes therapeutic products (AMOR-18 for COVID-19, AMOR-1 for hypoparathyroidism, and investigational therapies for pancreatic cancer, Crohn's disease) along with consumer calcium supplements. The ACC platform delivers highly bioavailable minerals that respond to acidic microenvironments, making it applicable across bone and metabolic disorders, inflammatory diseases, and oncology. The technology is inspired by the blue crayfish's ability to rapidly build exoskeletons using amorphous calcium carbonate.

Product and service5 records
1Amorphous Calcium Carbonate (ACC) Platform
CategoryCore Platform Technology
2ACC Calcium Supplements
CategoryConsumer Health Product
3AMOR-18 (COVID-19 Therapeutic)
CategoryTherapeutic Product (Inflammatory/Infectious Disease)
4AMOR-1 (Hypoparathyroidism Therapy)
CategoryTherapeutic Product (Bone & Metabolic Disease)
5Nano-Amorphous Mineral Therapy for Stage IV Pancreatic Cancer
Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-24
Description

Single-center clinical partnership for Stage IV pancreatic cancer Phase 2 trial led by Principal Investigator Dr. Offer Porim, evaluating nano-amorphous carbonate therapy as adjunct to standard of care with enrollment of 10 participants and follow-up for up to 12 months

2Rambam Medical Center - Bone and Mineral Metabolism Unit
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Clinical study (AMCS009) conducted by the Bone and Mineral Metabolism Unit evaluating ACC in patients with chronic primary hypoparathyroidism, demonstrating stable calcium control with 50% reduction in elemental calcium dose

amorphical.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Multicenter Phase 1/2 clinical trial for COVID-19 (AMOR-18) conducted across three Israeli medical centers during Delta and early Omicron waves, demonstrating zero ICU transfers or deaths in treatment arm

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage biotech developing oral delivery of therapeutics for bone and metabolic diseases, including hypoparathyroidism and osteoporosis. Most directly comparable given shared focus on novel oral delivery for underserved bone/parathyroid indications.

TypeBroad incumbent
Description

Established rare-disease biotech with TransCon PTH (palopegteriparatide) for hypoparathyroidism directly competing with Amorphical's AMOR-1. Larger, well-funded competitor with completed Phase 3 data and BLA filing in the same indication.

TypeBroad incumbent
Description

Bone health-focused biopharma with Tymlos (abaloparatide) for osteoporosis. Comparable in targeting bone and metabolic diseases with novel mineral/peptide therapeutics.

4Bone Therapeutics
TypeDirect peer
Description

Clinical-stage biotech developing bone cell therapy and regenerative solutions for orthopedic conditions and bone diseases. Comparable platform approach to addressing bone and metabolic disorders with novel mineral/biologic delivery.

TypeBroad incumbent
Description

Rare disease biotech with established hypoparathyroidism franchise (Crysvita/burosumab for XLH) and broader mineral metabolism focus. Comparable in targeting rare endocrine bone disorders with novel mineral pathway therapeutics.

TypeEmerging player
Description

Cell therapy biotech with remestemcel-L for inflammatory diseases including potential Crohn's applications. Comparable in pursuing non-immunosuppressive approaches to inflammatory conditions where Amorphical positions ACC.

TypeEmerging player
Description

Late-stage clinical biotech with novel therapeutic platform approach across multiple indications. Comparable as similarly-sized platform biotech pursuing first-in-class mechanisms across diverse disease areas.

TypeBroad incumbent
Description

Global biopharma with Prolia/Xgeva (denosumab) for osteoporosis and bone metastases. Represents the incumbent competitive benchmark in bone therapeutics that Amorphical's bone/metabolic pipeline must differentiate against.

TypeOthers
Description

Life sciences tools and clinical diagnostics company with bone metabolism research reagents. Adjacent connection through shared expertise in calcium signaling, mineral metabolism research tools, and bone health biomarkers.

TypeDirect peer
Description

Clinical-stage biotech developing novel therapeutics targeting TGF-beta superfamily for blood and bone disorders. Comparable as similarly-sized clinical biotech platform company pursuing first-in-class mechanisms across bone and hematologic indications.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Amorphical

Biopharmaceuticals / Mineral Therapeuticsamorphical.com

Amorphical is an Israeli clinical-stage biotechnology company developing nano-amorphous calcium carbonate (ACC) therapeutics for hypoparathyroidism, Crohn's disease, pancreatic cancer, and COVID-19, and selling ACC-based calcium supplements directly to consumers, supported by nearly 200 patents and a GMP-certified production facility.

What Amorphical does

Amorphical is a privately held Israeli biotechnology company founded in 2004 and headquartered in Ness Ziona, Israel. It develops therapeutics based on a proprietary nano-amorphous calcium carbonate (ACC) platform technology inspired by the blue crayfish's ability to store calcium in amorphous (non-crystalline) form for rapid exoskeleton regeneration. The disordered, nanometric mineral structure (10-100 nm particle size) provides approximately double the fractional calcium absorption of crystalline calcium carbonate (22.1% vs 13.7%) and dissolves preferentially in acidic microenvironments, enabling targeted delivery to sites of inflammation, tumor acidity, and metabolic dysfunction while sparing healthy tissue. The company has built a portfolio of nearly 200 patent applications (more than 130 granted) and a 3,200 sq.m. GMP/ISO/HACCP-certified production facility in the Arava Desert.

Amorphical operates four clinical-stage therapeutic programs: AMOR-1 (Phase 2 under FDA IND for hypoparathyroidism, 81 participants, demonstrating 50% dose reduction), AMOR-18 (Phase 1/2 for moderate-to-severe COVID-19 showing 0% ICU transfers/deaths vs 23% placebo), an enteric-coated ACC program for moderate-to-severe Crohn's disease (Phase 2 with 62.5% sustained remission at 48 weeks), and a Phase 2 trial for Stage IV pancreatic cancer launched at Shaare Zedek Medical Center in November 2025. In parallel, the company sells ACC-based calcium supplements directly to consumers as a higher-bioavailability alternative to conventional calcium products.

The business model combines long-term pharmaceutical development — targeting FDA-regulated approvals and potential licensing/royalty economics in bone/metabolic disease, inflammatory disease, and oncology — with a smaller near-term commercial supplements revenue stream. Clinical work is conducted exclusively through partnerships with leading Israeli medical centers, and the company has assembled a leadership team with pharmaceutical veterans from Teva (Copaxone development) and SRI International. No revenue, funding total, or commercial scale figures are publicly disclosed.

Amorphical firmographics

Firmographics
Name
Amorphical
Legal name
Amorphical Ltd.
Website
https://amorphical.com
Company type
Private
Founded year
2004
Operating status
Operating
Headcount range
11–50 employees
Short description
Amorphical is an Israeli clinical-stage biotechnology company developing nano-amorphous calcium carbonate (ACC) therapeutics for hypoparathyroidism, Crohn's disease, pancreatic cancer, and COVID-19, and selling ACC-based calcium supplements directly to consumers, supported by nearly 200 patents and a GMP-certified production facility.
Ownership category
akta.pro rank

Amorphical industry classification

Industry
Product category
Biopharmaceuticals / Mineral Therapeutics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Ground or Treated Mineral and Earth Manufacturing (327992)
SIC
Pharmaceutical Preparations (2834), Industrial Inorganic Chemicals (2810)
akta.pro industry
PRIMARYAFAJAKAB
Minerals & Trace Elements (Calcium, Magnesium, Zinc, Iron; Chelated Minerals)
Agriculture & Food Production/Food Ingredients & Additives/Nutraceutical & Functional Ingredients (Vitamins, Minerals, Omega-3s, Botanicals)
SECONDARYHLAHAEAG
Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)

Keywords

  • Amorphous calcium carbonate
  • Biopharmaceutical therapeutics
  • Mineral-based medicine
  • Calcium supplements
  • Clinical stage drugs

Where Amorphical is headquartered

Location

Headquarters

HQ city
Ness Ziona
HQ country
Israel
HQ region
Middle East

Offices2 records

Markets served

Amorphical business model

Business model
GTM type
B2B and B2C
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Operations, Personnel, Infrastructure, Marketing or Sales

Revenue model

  1. ACC-based calcium supplements: Commercial sale of amorphous calcium carbonate supplements for bone health, positioning as superior alternative to conventional calcium supplements for consumers seeking enhanced bioavailability
  2. Pharmaceutical development: Development and potential future commercialization of nano-amorphous mineral therapeutics for inflammatory diseases, metabolic disorders, and oncology through FDA-regulated clinical pathways
  3. Oncology adjunct therapy: Stage IV pancreatic cancer Phase 2 clinical trial evaluating nano-amorphous mineral therapy as adjunct to standard chemotherapy, with data expected Q3 2026

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Amorphical product offering

Product offering

Core offering

Amorphical develops and manufactures proprietary nano-amorphous calcium carbonate (ACC)-based therapeutics and supplements derived from biomimicry of the blue crayfish gastrolith. The company sells commercial ACC calcium supplements for bone health (B2C) and advances a clinical-stage pipeline of therapeutic candidates targeting hypoparathyroidism (AMOR-1, Phase 2), Crohn's disease, Stage IV pancreatic cancer, and previously COVID-19 (AMOR-18), with multiple delivery formulations including oral, inhaled, enteric-coated, and topical.

Product overview

Amorphical operates as a biotechnology company offering a proprietary nano-amorphous mineral platform technology centered on Amorphous Calcium Carbonate (ACC). The company's portfolio includes therapeutic products (AMOR-18 for COVID-19, AMOR-1 for hypoparathyroidism, and investigational therapies for pancreatic cancer, Crohn's disease) along with consumer calcium supplements. The ACC platform delivers highly bioavailable minerals that respond to acidic microenvironments, making it applicable across bone and metabolic disorders, inflammatory diseases, and oncology. The technology is inspired by the blue crayfish's ability to rapidly build exoskeletons using amorphous calcium carbonate.

Differentiator

Problem solved

Functional benefit

Products and services

  • Amorphous Calcium Carbonate (ACC) Platform
  • ACC Calcium Supplements
  • AMOR-18 (COVID-19 Therapeutic)
  • AMOR-1 (Hypoparathyroidism Therapy)
  • Nano-Amorphous Mineral Therapy for Stage IV Pancreatic Cancer

Quantifiable outcome

  • 62.5% sustained clinical remission at 48 weeks in Crohn's disease Phase 2 trial
  • +3 more outcomes

Companies that use Amorphical

Customer profile

Named customers6 records

Segments5 records

Ideal customer profiles4 records

Amorphical technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Amorphical partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • Shaare Zedek Medical CentercoreStrategic or Co-development Partner · 24 November 2025Single-center clinical partnership for Stage IV pancreatic cancer Phase 2 trial led by Principal Investigator Dr. Offer Porim, evaluating nano-amorphous carbonate therapy as adjunct to standard of care with enrollment of 10 participants and follow-up for up to 12 months
  • Rambam Medical Center - Bone and Mineral Metabolism UnitcoreStrategic or Co-development PartnerClinical study (AMCS009) conducted by the Bone and Mineral Metabolism Unit evaluating ACC in patients with chronic primary hypoparathyroidism, demonstrating stable calcium control with 50% reduction in elemental calcium dose
  • Israeli Medical Centers (Ziv, Shamir, Kaplan)coreStrategic or Co-development PartnerMulticenter Phase 1/2 clinical trial for COVID-19 (AMOR-18) conducted across three Israeli medical centers during Delta and early Omicron waves, demonstrating zero ICU transfers or deaths in treatment arm

Scale indicators8 records

Recent moves7 records

Expansion highlights5 records

Amorphical competitors and assessment

Company assessment

Direct peers

  • Entera Bio: Clinical-stage biotech developing oral delivery of therapeutics for bone and metabolic diseases, including hypoparathyroidism and osteoporosis. Most directly comparable given shared focus on novel oral delivery for underserved bone/parathyroid indications.
  • Bone Therapeutics: Clinical-stage biotech developing bone cell therapy and regenerative solutions for orthopedic conditions and bone diseases. Comparable platform approach to addressing bone and metabolic disorders with novel mineral/biologic delivery.
  • Keros Therapeutics: Clinical-stage biotech developing novel therapeutics targeting TGF-beta superfamily for blood and bone disorders. Comparable as similarly-sized clinical biotech platform company pursuing first-in-class mechanisms across bone and hematologic indications.

Broad incumbents

  • Ascendis Pharma: Established rare-disease biotech with TransCon PTH (palopegteriparatide) for hypoparathyroidism directly competing with Amorphical's AMOR-1. Larger, well-funded competitor with completed Phase 3 data and BLA filing in the same indication.
  • Radius Health: Bone health-focused biopharma with Tymlos (abaloparatide) for osteoporosis. Comparable in targeting bone and metabolic diseases with novel mineral/peptide therapeutics.
  • Ultragenyx Pharmaceutical: Rare disease biotech with established hypoparathyroidism franchise (Crysvita/burosumab for XLH) and broader mineral metabolism focus. Comparable in targeting rare endocrine bone disorders with novel mineral pathway therapeutics.
  • Amgen: Global biopharma with Prolia/Xgeva (denosumab) for osteoporosis and bone metastases. Represents the incumbent competitive benchmark in bone therapeutics that Amorphical's bone/metabolic pipeline must differentiate against.

Emerging players

  • Mesoblast: Cell therapy biotech with remestemcel-L for inflammatory diseases including potential Crohn's applications. Comparable in pursuing non-immunosuppressive approaches to inflammatory conditions where Amorphical positions ACC.
  • Tarsus Pharmaceuticals: Late-stage clinical biotech with novel therapeutic platform approach across multiple indications. Comparable as similarly-sized platform biotech pursuing first-in-class mechanisms across diverse disease areas.

Others

  • Bio-Techne: Life sciences tools and clinical diagnostics company with bone metabolism research reagents. Adjacent connection through shared expertise in calcium signaling, mineral metabolism research tools, and bone health biomarkers.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Amorphical social profiles

Digital presence

Amorphical compliance and trust

Trust signal

Compliance5 records

Amorphical financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Amorphical leadership team

Management profile

Number of profiles

Profiles12 records

Amorphical funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Amorphical M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Amorphical

What does Amorphical do?

Amorphical develops and manufactures proprietary nano-amorphous calcium carbonate (ACC)-based therapeutics and supplements derived from biomimicry of the blue crayfish gastrolith. The company sells commercial ACC calcium supplements for bone health (B2C) and advances a clinical-stage pipeline of therapeutic candidates targeting hypoparathyroidism (AMOR-1, Phase 2), Crohn's disease, Stage IV pancreatic cancer, and previously COVID-19 (AMOR-18), with multiple delivery formulations including oral, inhaled, enteric-coated, and topical.

Is Amorphical a public or private company?

Amorphical is a private company. It is classified as venture growth investor backed and is currently operating.

When was Amorphical founded?

Amorphical was founded in 2004. It employs 11 to 50 people.

Where is Amorphical based?

Amorphical is headquartered in Ness Ziona, Israel, in the Middle East region.

How does Amorphical make money?

Three revenue lines are on record. ACC-based calcium supplements are the primary driver. The others are pharmaceutical development and oncology adjunct therapy.

Who are Amorphical's main competitors?

Direct peers on record are Entera Bio, Bone Therapeutics and Keros Therapeutics. Broad incumbents are Ascendis Pharma, Radius Health, Ultragenyx Pharmaceutical and Amgen. Emerging players are Mesoblast and Tarsus Pharmaceuticals. Bio-Techne is listed as an others.

Does Amorphical have an API?

No public API is recorded for Amorphical.

What industry is Amorphical in?

Amorphical's product category is Biopharmaceuticals / Mineral Therapeutics. Its primary akta.pro industry code is AFAJAKAB, Minerals & Trace Elements (Calcium, Magnesium, Zinc, Iron; Chelated Minerals), with a secondary code of HLAHAEAG, Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM). Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Pulse 2.0Amorphical: Interview With CEO Eden Ben About The Biotechnology CompanyAmorphical, a biotechnology company, is developing a nano-amorphous mineral platform based on a discovery from crayfish exoskeleton regeneration, with four therapeutics currently in clinical trials covering hypoparathyroidism, osteoporotic fractures, Crohn's disease, and Stage IV pancreatic cancer. The company, led by CEO Eden Ben who became CEO in 2025 after rising through operations and R&D roles, recently reported positive long-term data from its Crohn's trial showing nearly two-thirds of patients achieved sustained clinical remission through 24 weeks. Amorphical is seeking a $90M-$110M funding round and preparing for a Nasdaq IPO, with initial regulatory submissions projected for 2030.PR NewswireAmorphical Announces Full Patient Enrollment in Phase 2 FDA Clinical Trial of AMOR-1 for the Treatment of HypoparathyroidismAmorphical completed patient enrollment in its Phase 2 FDA trial of AMOR-1 for hypoparathyroidism, with 50 adult participants randomized 2:1. The trial aims to reduce elemental calcium intake by 50% while maintaining serum calcium, with final data readout expected in Q4 2026.PR NewswireAmorphical to Present Long-Term Phase 2 Crohn's Disease Data at the 21st Congress of ECCOAmorphical announced that long-term Phase 2 trial data for its nano-amorphous calcium carbonate (ACC) therapy in moderate-to-severe Crohn's disease will be presented at the ECCO Congress in Berlin on February 20, 2026. The data confirms 62.5% sustained clinical remission (CDAI <150) at 48 weeks, demonstrating the therapy's durability without the systemic risks of immunosuppression. These findings will support Amorphical's upcoming regulatory submissions and planned expansion of its Crohn's clinical program into the United States.PR NewswireAmorphical Announces Positive Final Long-Term Results from Phase 2 Crohn's Disease Trial: Results Confirm Efficacy and Show Sustained Clinical RemissionAmorphical announced positive final long-term results from its Phase 2 clinical trial for nano-amorphous Calcium Carbonate (ACC) therapy, confirming efficacy and sustained clinical remission in patients with moderate-to-severe Crohn's disease. The data demonstrated that ACC significantly reduced disease activity scores compared to placebo and maintained benefits over follow-up periods extending up to 97 weeks. The company now plans to engage with the FDA and investment community to advance the therapy into subsequent development phases.PR NewswireAmorphical Announces First Patient Enrolled in Phase 2 Clinical Trial of Nano-Amorphous Mineral-Based Therapy in Stage IV Pancreatic Cancer PatientsAmorphical announced the enrollment of the first patient in its Phase 2 clinical trial evaluating a nano-amorphous mineral-based therapy for Stage IV pancreatic cancer, approved by the Helsinki Committee of Shaare Zedek Medical Center and the Israel Ministry of Health. The trial will measure progression-free survival, overall survival, response rate, and quality of life, with data expected in Q3 2026. The therapy aims to normalize tumor acidity—a hallmark of advanced pancreatic cancer that contributes to immune evasion, metastasis, and treatment resistance.PR NewswireAmorphical Announces Positive Interim Results from Ongoing Clinical Trial in Crohn's DiseaseAmorphical announced positive interim results from an ongoing open-label clinical trial evaluating its investigational nano-amorphous calcium carbonate therapy for moderate-to-severe Crohn's disease, conducted at Soroka University Medical Center in Israel. Of 17 patients with available data, 71% (12/17) experienced clinical improvement exceeding 100 CDAI points and 47% (8/17) achieved clinical remission, with no safety concerns observed. The company plans to leverage these results to inform a future FDA regulatory strategy, with additional data expected upon unblinding of the double-blind phase in November.PR NewswireAmorphical Appoints Eden Ben as CEO, as Company Advances Regulatory Pathway for Nano-Amorphous Mineral-Based TherapeuticsAmorphical, an Israeli biotechnology company developing nano-amorphous mineral-based therapeutics, announced the appointment of Eden Ben as its new CEO to guide regulatory strategy in the U.S. and Europe and advance its pipeline of disease-modifying therapies. The company's clinical program includes a Phase 2 trial for hypoparathyroidism under FDA review, with additional studies for pancreatic cancer, osteoporotic fractures, and Crohn's disease under regulatory review. Amorphical enters clinical development backed by over a decade of real-world experience from early access and compassionate use programs, along with nearly 200 patents and GMP-certified manufacturing infrastructure.ynetHealthy Israeli delicacy: Protein from locustsAt a Tel Aviv food-tech lecture, speakers presented insect-based protein powders and other food products. Dror Tamir of Hargol FoodTech showcased grasshopper protein powder, while Yossi Ben of Amorpical highlighted crustacean-derived calcium. The event also featured red grape cell powder from BioHarvest.